The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Eli Lilly and Company (LLY) is a leading drug manufacturers - general business with stocks listed in the US. It closed the previous market day at US$1020.84. During the previous open market day, the price has varied from a low of USD1005.83 to a high of USD1075. Eli Lilly and Company is listed on the NYSE. All prices are listed in US Dollars.
How to buy shares in Eli Lilly and Company
- Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Eli Lilly and Company. Find the share by name or ticker symbol: LLY. Research its history to confirm it's a solid investment that matches your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Eli Lilly and Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$1020.84, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Eli Lilly and Company, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Eli Lilly and Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.
Compare trading platforms to buy Eli Lilly and Company shares
Compare other products
We currently don't have that product, but here are others to consider:
How we picked theseFinder Score for share trading platforms
We've scored over 30 share trading platforms assessing them for their core features, fees, customer experience and accessibility. Our experts give each platform a score out of 10.
Have Eli Lilly and Company's shares ever split?
Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Eli Lilly and Company shares at a glance
Information last updated 2026-02-03.
| 52-week range | US$621.5001 - US$1133.95 |
|---|---|
| 50-day moving average | US$1055.1274 |
| 200-day moving average | US$854.6473 |
| Target price | US$1150 |
| PE ratio | 49.2617 |
| Dividend yield | US$5.8 (0.56%) |
| Earnings per share (TTM) | US$20.37 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Eli Lilly and Company price performance over time
Historical closes compared with the last close of $1020.84
| 1 week (2026-01-30) | -1.57% |
|---|---|
| 1 month (2026-01-06) | -4.06% |
| 3 months (2025-11-06) | 8.90% |
| 6 months (2025-08-06) | 36.77% |
| 1 year (2025-02-06) | 17.29% |
|---|---|
| 2 years (2024-02-06) | 44.79% |
| 3 years (2023-02-06) | 202.33% |
| 5 years (2021-02-05) | 405.94% |
Is it a good time to buy Eli Lilly and Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is it worth buying Eli Lilly and Company stock?
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's P/E ratio
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, Eli Lilly and Company shares trade at around 49x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's PEG ratio
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.943. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$28.7 billion (£21.6 billion).
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure stock profitability.
Eli Lilly and Company share price volatility
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as US$621.5001 up to US$1133.95. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.394. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company financials
| Revenue TTM | US$59.4 billion |
|---|---|
| Operating margin TTM | 48.29% |
| Gross profit TTM | US$49.3 billion |
| Return on assets TTM | 17.6% |
| Return on equity TTM | 96.47% |
| Profit margin | 30.99% |
| Book value | 26.56 |
| Market capitalisation | US$899.6 billion |
| EBITDA | US$28.7 billion |
TTM: trailing 12 months
Eli Lilly and Company share dividends
Dividend payout ratio: 37.37% of net profits
Recently Eli Lilly and Company has paid out, on average, around 37.37% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.62% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0.62% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $5.8 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 March 2026. The latest dividend was paid out to all shareholders who bought their shares by 12 February 2026 (the "ex-dividend date").
Eli Lilly and Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Eli Lilly and Company's total ESG risk score
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
| Total ESG score | 32.36 |
|---|---|
| Total ESG percentile | 70.22 |
| Environmental score | 0.63 |
| Environmental score percentile | 1 |
| Social score | 16.68 |
| Social score percentile | 1 |
| Governance score | 13.31 |
| Governance score percentile | 1 |
| Level of controversy | 3 |
Eli Lilly and Company overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation. The company also has a research collaboration agreement with Insilico Medicine for the development of advance therapies; and Nimbus Therapeutics, LLC for the development of novel oral treatment for obesity and other metabolic diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Frequently asked questions
Sources
More resources on Finder
Ask a question
More guides on Finder
-
The best trading platforms in Australia for beginners
Looking to start investing? Here are our top 6 online trading platforms for total beginners in Australia.
-
Best stocks under $5 in Australia (2026)
We used Finder's proprietary algorithm to find Australian-listed companies that have strong fundamentals and have a share price under $5.
-
The best ASX penny stocks (updated weekly)
Best performers included Latitude 66, Cosmos Exploration and Javelin Minerals.
-
The best ASX shares to buy in February 2026
Here are our algorithm-selected 20 Aussie stocks worth watching in 2026.
-
What are the best AI stocks on the ASX in 2026? Stocks and ETFs to watch
Here's what investors should know before adding AI stocks to their portfolios.
-
How to invest in the S&P 500
Find out the different ways you can invest in the S&P 500 index from Australia.
-
Best ASX dividend stocks for 2026
Following a couple of lean years for dividend investors, here are 10 ideas you could consider in your portfolio.
-
How to invest in index funds in Australia
Index funds are a hot topic right now, but how do you actually invest in them?
-
How to buy gold in Australia
If you’re thinking of investing in gold, our guide will explain how and where to buy gold in Australia as well as the pros and cons of investing in it.
-
The cheapest trading platforms in Australia (February 2026)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.